Treatment patients advanced colorectal cancer cisplatin leucovorin vitro studies synergy LV cisplatin CDDP human colon cancer cell lines clinical trial effects combination patients advanced unresectable colorectal carcinoma Fifty-nine patients study prior conventional chemotherapy Treatment weekly courses high-dose LV intravenous IV bolus CDDP infusion consecutive days median treatment cycles objective tumor response patients complete remissions response rate untreated patients confidence limits Stable disease patients tumor patients median survival time months patients years regimen primary side effects mild reversible gastrointestinal symptoms myelosuppression episode life-threatening toxicity Eastern Cooperative Oncology Group ECOG Grade III adverse reactions dose reductions patients results trial LV CDDP active safe well-tolerated combination regimen patients advanced colorectal cancer 